InGell Labs BV (IGL – Groningen, The Netherlands) is an SME which develops injectable drug-depots for slow release of a broad range of therapeutic actives, all based on its patent-protected InGell®-platforms, and with rapid access to scale-up for cGMP processing. Applications are done with major Pharma companies in Diabetes, Pain management, OA, and CNS. Public-Private partnerships exist in orthopaedic, veterinary and oncology applications with UU-UMCU-UMCG-LUMC and UTwente. The company has developed two different polymer-based drug delivery platforms: InGell®-Gamma (hydrogel-depots) and InGell®-LQP (pure polymer depots). The platforms offer injectable drug delivery depots, which are formulated and delivered as liquids through thin needles (up to 31G).